Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma

被引:25
|
作者
Huang, Chun-Teng [1 ,2 ,4 ]
Liu, Chia-Jen [1 ,2 ]
Ko, Po-Shen [1 ,2 ]
Liu, Han-Tsung [1 ,2 ]
Yu, Yuan-Bin [1 ,2 ]
Hsiao, Liang-Tsai [1 ,2 ]
Gau, Jyh-Pyng [1 ,2 ]
Tzeng, Cheng-Hwai [1 ,2 ]
Chiou, Tzeon-Jye [2 ,3 ]
Liu, Jin-Hwang [1 ,2 ]
Yang, Muh-Hwa [2 ,6 ]
Huang, Ling-Ju [2 ,5 ]
Liu, Chun-Yu [2 ,6 ]
机构
[1] Taipei Vet Gen Hosp, Div Hematol & Oncol, Dept Med, Taipei, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Div Transfus Med, Dept Med, Taipei, Taiwan
[4] Taipei City Hosp, Div Hematol & Oncol, Dept Med, Yang Ming Branch, Taipei, Taiwan
[5] Taipei Vet Gen Hosp, Div Gen Med, Dept Med, 201,Sec 2,Shipai Rd, Taipei 11217, Taiwan
[6] Taipei Vet Gen Hosp, Div Med Oncol, Dept Oncol, Taipei, Taiwan
来源
BMC INFECTIOUS DISEASES | 2017年 / 17卷
关键词
Bloodstream infection; Multiple myeloma; Risk factor; ABSOLUTE LYMPHOCYTE COUNT; BACTERIAL-INFECTION; WORKING PARTY; COMPLICATIONS; BACTEREMIA; SURVIVAL; IMPACT;
D O I
10.1186/s12879-016-2155-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Patients with multiple myeloma are generally immune-compromised either due to pronounced depression in primary antibody responses or because of anti-myeloma therapy. Infection is a major risk factor for early deaths among these patients. The impact of blood stream infections (BSI) on newly diagnosed myeloma patients has been less studied. We aimed to study the incidence and risk factors of BSI within 3 months after diagnosis of multiple myeloma in a tertiary referral center. Methods: Between November 2002 and December 2008, consecutive patients with multiple myeloma in Taipei Veterans General Hospital were retrospectively enrolled. Characteristics of patients with or without BSI were collected. Possible factors associated with development of BSI were analyzed by Cox regression. Results: There were a total of 222 patients. The incidence of BSI within 3 months after diagnosis is 11.7%. The patients with BSI had poorer survival outcomes than those without (mortality rate: 50% vs. 20.9%, p < 0.001). Moreover, advanced International Staging System stage (stage III vs. I/II: odds ratio [OR] 2.69, p = 0.049) and poor Eastern Cooperative Oncology Group (ECOG) performance status (ECOG > 2 vs. <= 2: OR 3.58, p = 0.005) were the independent risk factors of BSI, whereas immunoglobulin deficiency and low absolute lymphocyte count were not associated with risk of BSI development. Conclusions: Our study highlights the characteristic of myeloma patients with BSI and the importance of disease and host factors on risk of BSI. Myeloma patients with risks of BSI should be properly managed to reduce early mortality.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Underweight as a risk factor of mortality in patients with newly diagnosed multiple myeloma
    Tsai, Chun-Kuang
    Yeh, Chiu-Mei
    Hsu, Te-Lin
    Li, Chia-Ju
    Tin, Chian
    Hsiao, Liang-Tsai
    Liu, Yao-Chung
    Wang, Hao-Yuan
    Ko, Po-Shen
    Chen, Po-Min
    Liu, Jin-Hwang
    Gau, Jyh-Pyng
    Liu, Chia-Jen
    SUPPORTIVE CARE IN CANCER, 2021, 29 (07) : 3991 - 3999
  • [22] Risk and Incidence of Venous Thromboembolism in Newly Diagnosed Multiple Myeloma Patients
    Nabar, Leeladhar
    Khan, Hamza
    Nair, Aditya
    Mishra, Dhyey
    Shah, Jash
    Lalwani, Devansh
    Talati, Shriraj
    Tembhare, Prashant
    Nayak, Lingaraj
    Shetty, Alok
    Rajpal, Sweta
    Chatterjee, Gaurav
    Khan, Ajmat
    Mirgh, Sumeet
    Jindal, Nishant
    Gokarn, Anant
    Punatar, Sachin
    Jain, Hasmukh
    Patkar, Nikhil
    Shetty, Dhanlaxmi
    Subramanian, Papagudi
    Gujral, Sumeet
    Bagal, Bhausaheb
    Sengar, Manju
    Khattry, Navin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S121 - S121
  • [23] Development of a Clinical Risk Stratification for Patients with Newly Diagnosed Multiple Myeloma
    Mao, Xuehan
    Xu, Yan
    Yan, Yuting
    Liu, Jiahui
    Fan, Huishou
    Sui, Weiwei
    Deng, Shuhui
    Li, Zengjun
    Qiu, Lugui
    An, Gang
    BLOOD, 2019, 134
  • [24] Determination of the individual infection risk for newly diagnosed patients with multiple myeloma
    Kaebisch, E.
    Heck, C.
    Frentsch, M.
    Blau, I. -W
    Nogai, A.
    Bullinger, L.
    Na, I. -K
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 48 - 48
  • [25] Oprozomib in patients with newly diagnosed multiple myeloma
    Hari, Parameswaran
    Matous, Jeffrey V.
    Voorhees, Peter M.
    Shain, Kenneth H.
    Obreja, Mihaela
    Frye, John
    Fujii, Hisaki
    Jakubowiak, Andrzej J.
    Rossi, Davide
    Sonneveld, Pieter
    BLOOD CANCER JOURNAL, 2019, 9 (9)
  • [26] Oprozomib in patients with newly diagnosed multiple myeloma
    Parameswaran Hari
    Jeffrey V. Matous
    Peter M. Voorhees
    Kenneth H. Shain
    Mihaela Obreja
    John Frye
    Hisaki Fujii
    Andrzej J. Jakubowiak
    Davide Rossi
    Pieter Sonneveld
    Blood Cancer Journal, 9
  • [27] Inferior vena cava filters do not increase the risk of blood stream infections in patients with newly diagnosed VTE
    Chua, Abigail T.
    Murphy, Charles G.
    Hameed, Shahistha
    Weston, Gregory
    Abramowitz, Matthew
    Gershengorn, Hayley
    Fein, Daniel G.
    AMERICAN JOURNAL OF INFECTION CONTROL, 2020, 48 (12) : 1491 - 1496
  • [28] HLC PAIR SUPPRESSION AS A RISK FACTOR FOR BLOODSTREAM INFECTIONS AND EARLY DEATH IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    De Veas Silva, J. L. Garcia
    Lopez Velez, M. D. S.
    Bermudo Guitarte, C.
    Barbosa de Carvalho, N.
    Rios Tamayo, R.
    Jurado Chacon, M.
    De Haro Munoz, T.
    HAEMATOLOGICA, 2017, 102 : 526 - 526
  • [29] Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis
    Bonello, Francesca
    D'Agostino, Mattia
    Offidani, Massimo
    Petrucci, Maria Teresa
    Liberati, Anna Marina
    Patriarca, Francesca
    Capra, Andrea
    Benevolo, Giulia
    Gaidano, Gianluca
    Barila, Gregorio
    Galli, Monica
    Ponticelli, Elena
    Cascavilla, Nicola
    Angelucci, Emanuele
    Ballanti, Stelvio
    Pietrantuono, Giuseppe
    Pulini, Stefano
    Derudas, Daniele
    de Fabritiis, Paolo
    Corradini, Paolo
    Conticello, Concetta
    Cavo, Michele
    Sonneveld, Pieter
    Boccadoro, Mario
    Bringhen, Sara
    BLOOD, 2020, 136
  • [30] Individualized risk stratification in newly diagnosed multiple myeloma
    Rajanna, Arjun Raj
    Maura, Francesco
    Derkach, Andriy
    Ziccheddu, Bachisio
    Weinhold, Niels
    Maclachlan, Kylee
    Diamond, Benjamin
    Davies, Faith
    Boyle, Eileen
    Walker, Brian
    Pos, Alexandra
    Hulcrantz, Malin
    Silva, Ariosto
    Hampton, Oliver
    Teer, Jamie K.
    Bolli, Niccolo
    Jackson, Graham
    Kaiser, Martin
    Pawlyn, Charlotte
    Cook, Gordon
    Verducci, Dennis
    Kazandjian, Dickran
    Van Rhee, Fritz
    Usmani, Saad
    Shain, Kenneth H.
    Raab, Marc S.
    Morgan, Gareth
    Landgren, Ola
    CANCER RESEARCH, 2023, 83 (07)